Abstract
MicroRNAs are post-transcriptional regulators of gene expression with tissue-specific expression profiles. Dysregulation of microRNAs has been shown to play a role in carcinogenesis. Although progress has been made in the diagnosis and treatment of many cancers, pancreatic cancer remains an intractable public health problem, causing 6.58% of cancer deaths despite making up less than 3% of cancer diagnoses in the United States. No screening, diagnostic or imaging techniques exist with the sensitivity to detect pancreatic cancer in its early, operable stages. Risk factors include numerous inherited syndromes, diabetes mellitus, and hepatitis C virus infection. Here we review the literature regarding dysregulation of microRNA expression in native pancreas, pancreatic ductal adenocarcinoma (the dominant form of pancreatic cancer), and its risk factors to illuminate the biology and progression of this disease. We explore promising evidence for the use of microRNAs as prognostic and diagnostic tools, and discuss emerging reports on microRNA therapeutics.
Keywords: Biomarker, microRNA, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, carcinogenesis, malignancy, asymptomatic, papillary, serum, Endocrine.
MicroRNA
Title:No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma
Volume: 1 Issue: 1
Author(s): Philip Y. Cheung, Anna E. Szafranska-Schwarzbach, Annette M. Schlageter, Bernard F. Andruss and Glen J. Weiss
Affiliation:
Keywords: Biomarker, microRNA, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, carcinogenesis, malignancy, asymptomatic, papillary, serum, Endocrine.
Abstract: MicroRNAs are post-transcriptional regulators of gene expression with tissue-specific expression profiles. Dysregulation of microRNAs has been shown to play a role in carcinogenesis. Although progress has been made in the diagnosis and treatment of many cancers, pancreatic cancer remains an intractable public health problem, causing 6.58% of cancer deaths despite making up less than 3% of cancer diagnoses in the United States. No screening, diagnostic or imaging techniques exist with the sensitivity to detect pancreatic cancer in its early, operable stages. Risk factors include numerous inherited syndromes, diabetes mellitus, and hepatitis C virus infection. Here we review the literature regarding dysregulation of microRNA expression in native pancreas, pancreatic ductal adenocarcinoma (the dominant form of pancreatic cancer), and its risk factors to illuminate the biology and progression of this disease. We explore promising evidence for the use of microRNAs as prognostic and diagnostic tools, and discuss emerging reports on microRNA therapeutics.
Export Options
About this article
Cite this article as:
Y. Cheung Philip, E. Szafranska-Schwarzbach Anna, M. Schlageter Annette, F. Andruss Bernard and J. Weiss Glen, No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma, MicroRNA 2012; 1 (1) . https://dx.doi.org/10.2174/2211536611201010049
DOI https://dx.doi.org/10.2174/2211536611201010049 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia
Current Neuropharmacology Chronic Pancreatitis and the Development of Pancreatic Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Blood Pressure and the Risk of Dementia: A Dose-Response Meta-Analysis of Prospective Studies
Current Neurovascular Research Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects
Current Medicinal Chemistry Associations between Adiponectin Gene Variability, Proinflammatory and Angiogenetic Markers: Implications for Microvascular Disease Development in Type 2 Diabetes Mellitus?
Current Vascular Pharmacology Management of Obesity in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Serum Pro-oxidant-antioxidant Balance in Subjects with Type 2 Diabetes Mellitus
Combinatorial Chemistry & High Throughput Screening Diet and Contaminants: Driving the Rise to Obesity Epidemics?
Current Medicinal Chemistry Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?
Current Clinical Pharmacology Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Current Pharmaceutical Design Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]
Current Vascular Pharmacology Portal Vein Embolization: A Preoperative Approach to Improve the Safety of Major Hepatic Resection
Current Medical Imaging Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Paraoxonase-1: Characteristics and Role in Atherosclerosis and Carotid Artery Disease
Current Vascular Pharmacology Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets